Lynozyfic J Code: J9601
Injection, linvoseltamab-gcpt, 1 mg
Q4 2026 Medicare Payment Limit for J9601, effective October 1, 2026: $99.134 per HCPCS billing unit, down 0.2% from $99.305. From CMS's final file.
Drug & Product Overview
About Lynozyfic
Lynozyfic is a medication aligned to the HCPCS J Code: J9601 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous route and manufactured by Regeneron Pharmaceuticals, Inc.
Manufacturers, reach out to us to add more information.
NDC Code Information
Based on publicly available CMS files. The list of NDCs below is not exhaustive.
| NDC Code | Package | Manufacturer | HCPCS Units | WAC | AWP |
|---|---|---|---|---|---|
| 61755-0054-01 | 5 MG / 2.5 MLLynozyfic Intravenous Injection 5 MG/2.5ML - 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-054-01) / 2.5 mL in 1 VIAL, SINGLE-DOSE (61755-054-00) | Regeneron Pharmaceuticals, Inc. | 5 | $470.00 $94.00 / unit | $564.00 $112.80 / unit |
| 61755-0056-01 | 200 MG / 10 MLLynozyfic Intravenous Injection 200 MG/10ML - 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-056-01) / 10 mL in 1 VIAL, SINGLE-DOSE (61755-056-00) | Regeneron Pharmaceuticals, Inc. | 200 | $18,800.00 $94.00 / unit | $22,560.00 $112.80 / unit |
Effective 7/2/25 (WAC & AWP)
Lynozyfic Pricing & Reimbursement
Historical Graphing and Billing Calculator
Estimates only. Payer reimbursement varies by contract, site of care, and sequestration.
Lynozyfic Claims Performance
Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.
Explore J9601 claims analytics on FocalPoint →
Lynozyfic CPT Administration Codes
The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.
| CPT Code | Description |
|---|---|
| 96413 | Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug |
| 96415 | Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) |
This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →
Lynozyfic Clinical Information
Indications and drug classification.
This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.
Login for BuyandBill.com Analytics
Unlock deeper insights with BuyandBill’s Comparative Report!
- Compare ASP, WAC, and AWP across drugs.
- Visualize Drug Price Movement Over Time
- Tailor reports to drug class, manufacturer, or HCPCS Code.
- Compare Biosimilar and 505(b)(2) products.
Frequently Asked Questions
Is there an available Lynozyfic billing and coding guide?
Are there any available Lynozyfic patient assistance programs?
Where can I find Lynozyfic prescribing information?
Where can I find Lynozyfic side effect information?
Does billing Lynozyfic require JZ/JW wastage modifiers?
About BuyandBill.com:
The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.
Related Drug Codes
Explore billing, coding, and pricing for drugs related to Lynozyfic.